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 The opioid epidemic in the United States has been a growing problem over the past two 
decades. There were 2.1 million people in the United States who met the clinical criteria for an 
opioid use disorder in 2016. Of these people, less than a third of them received evidence based 
treatment. This thesis focuses on one of the promising forms of treatment for opioid use disorder: 
medically assisted maintenance (MAT) using buprenorphine. This thesis aimed to answer the 
following question. How well do the innovative ways for providing medically assisted treatment 
using buprenorphine address the current barriers to access in the United States?  
 In order to answer this question, the thesis is broken into three parts. The first chapter 
focuses on the evidence supporting buprenorphine as an effective treatment for opioid use 
disorder. The second chapter focuses on identifying the current barriers to accessing 
buprenorphine for MAT in the United States. The third chapter focuses on four innovative 
methods for providing treatment with buprenorphine: project ECHO, hub and spoke, 
collaborative care, and hospital initiation of buprenorphine. These innovations were assessed 
based on their ability to address some of the key barriers to access that were identified in chapter 
2 of the thesis.  
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Introduction: 
 
The opioid crisis in the United States has been a growing problem over the past two 
decades. While at times incredibly valuable for their analgesic properties, opioids also have habit 
forming properties that put the people using them at risk of developing an opioid use disorder. In 
2017, an estimated 49,068 people in the US died from opioid overdoses.1 Despite the growing 
national attention and attempts to reduce the damage of the opioid epidemic in recent years, the 
number of opioid overdoses has been growing annually, with a 28% increase in the number of 
overdoses between 2015 and 2016.2 The opioid epidemic has also resulted in approximately 2.1 
million people in the United States reaching the clinical criteria for diagnosis of an opioid use 
disorder (OUD) in 2016.3 Of those with an opioid use disorder, only 29.9% received evidence 
based treatment.4 The root cause of this epidemic is multifaceted and complex, which can 
complicate attempts to address the epidemic. While the problem of opioids is considerable, there 
are promising treatments for people with opioid use disorders. Pharmacological treatment of 
opioid use disorder, called medically assisted treatment (MAT), is one of these promising and 
effective form of treatment. Despite the known efficacy of this type of treatment, there continue 
to be problems with ensuring access to MAT for patients in the US. This thesis will focus on 
efforts to expand access to medically assisted treatment using buprenorphine. The thesis will 
attempt to answer the following question: How well do the innovative ways for providing 
medically assisted treatment using buprenorphine address the current barriers to access in the 
                                                        
1 National Center on Health Statistics, “National Overdose Deaths from Select Prescription and Illicit Drugs,” 
August 2018.” 
2 National Center on Health Statistics. 
3 SAMHSA, Key Substance Use and Mental Health Indicators in the United States: Results from the 2017 National 
Survey on Drug Use and Health 
4 SAMHSA. 
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United States? This thesis will address this question in three chapters. Chapter 1 will focus on 
why providing access to treatment of opioid use disorder with buprenorphine is a necessary and 
effective response to the opioid epidemic. Chapter 2 will assess some of the barriers to accessing 
this form of treatment. Chapter 3 will analyze some of the innovations in providing treatment for 
OUD with buprenorphine and how these innovations address the current barriers to access.  
Chapter 1: Why Increasing Access to MAT is a Promising Response 
the Opioid Epidemic 
 
History of the Opioid Epidemic in the United States: 
 
Since the discovery that opioids have analgesic and sedative properties, they have had 
both medicinal benefits and potentially harmful habit forming properties. Opioids have been 
present in American medicine for most of its history. One of the earliest forms of an opioid used 
in US medicine was morphine. Later, heroin was developed and popularized by Bayer 
Pharmaceutical in 1874.5 At that time, its purported uses included analgesic properties, cough 
suppression, and treatment for morphine addiction.6 The current opioid crisis is not the first time 
that the US has experiences an opioid epidemic. In the 1880s, the United States went through its 
first opioid epidemic. The rate of opioid prescription had been increasing since the mid 19th 
century mainly due to its widespread use as treatment for cough, diarrhea, and chronic pain. The 
habit forming nature of the drug was poorly understood and few alternative treatments were 
available. By the 1920s, the number of opioid overdose deaths and new cases of opioid 
addictions had decreased, mainly attributable to the development of alternative treatments and an 
                                                        
5 Wilkerson et al., “The Opioid Epidemic in the United States.” 
6 Wilkerson et al., “The Opioid Epidemic in the United States.” 
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increase in education amongst prescribers of the possible dangerous effects of opioid use.7 
Although the extent of opioid prevalence had subsided by the early 20th century, the problem 
continued to ruminate in the background and, beginning in the 1990s, developed into one of the 
worst drug epidemics seen in the United States.  
The opioid problem in the US began to worsen significantly in the 1990s and early 2000s. 
In 1986, a case study of 38 chronic pain patients claimed to show that opioids could safely be 
used in treatment of chronic pain.8 At that time, the addictive effects of newer opioids were not 
well understood and opioids were presented as a safe and effective treatment for chronic pain. 
Even when these addictive affects were better understood, the pharmaceutical companies and 
physicians did not effectively communicate the potential for addiction to their patients. In the 
1990’s a movement called “pain as the 5th vital sign” was widely popularized. The connotation 
of this campaign implied that pain was vital to health in the same way as other vitals such as 
blood pressure or body temperature. This movement incentivized doctors to aggressively treat 
pain and introduced pain reduction as a metric for clinical success.9 The rate of prescriptions for 
opioid more than quadrupled from 1996 to 2013. While increasing the access to opioids in an 
attempt to relieve pain was well intended, the increase had the unforeseen consequence of a 
concurrent quadrupling in the number of opioid overdoses in the United States. In 2017, 49,068 
people had died from an opioid overdose and approximately 2,110,000 Americans were living 
with a substance use disorder related to opioids.10 11 
                                                        
7 Wilkerson et al. 
8 Portenoy and Foley, “Chronic Use of Opioid Analgesics in Non-Malignant Pain.” 
9 Wilkerson et al., “The Opioid Epidemic in the United States.” 
10 National Center on Health Statistics, “National Overdose Deaths from Select Prescription and Illicit Drugs,” 
August 2018.” 
11 Center for Behavioral Health Statistics and Quality, 2017 National Survey on Drug Use and Health: Detailed 
Tables. 
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With 2.1 million Americans who have an opioid use disorder, it is imperative that 
evidence based treatment for OUD is widespread and easily accessible. One promising form of 
treatment is medically assisted treatment with buprenorphine or a buprenorphine-naltrexone 
combination. The history of the opioid epidemic helps to emphasize several lessons that are 
important when assessing the efficacy of increasing access to this form of MAT. While opioids 
are an essential medication for pain management, a lack of regulation, disregard for the potential 
risks, and common medical practices such as the “pain as the 5th vital sign” likely contributed to 
the unforeseen negative consequences of increasing access to opioids. In a similar way, MAT is 
an essential medication for treating opioid use disorder, but it is imperative that access be 
implemented in a way that both maximizes the benefits of the medication and minimizes its 
potential risks. One of the ways to increase the benefits of MAT treatment while mitigating the 
risks is to implement system based supports within the medical community. There are many 
models of providing this type of treatment that have been develop in recent years that aim to 
increase access to MAT in a way that also reduces any potential negative outcomes.  
 
Introduction to Opioid Use Disorder and Medically Assisted Treatment: 
There is significant unmet need for effective treatment of opioid use disorders. Medically 
assisted treatment is the use of pharmaceuticals to provide treatment for an opioid use disorder. 
There are currently three FDA approved pharmaceutical treatments for opioid use disorder:  
buprenorphine, methadone, and naltrexone. Both buprenorphine and methadone are opioid 
agonists, and they both activate the mu-opioid receptor. Long term use of either of these 
medications has been shown to retain patients and reduce the occurrence of illicit drug use better 
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than non-pharmaceutical based programs.12 These medications are a promising form of treatment 
for OUD, which has been historically difficult to treat. While these medication can be an 
necessary tool for recovery, it is important to acknowledge that both buprenorphine and 
methadone are forms of opioids. Long term use of these medications can cause physical 
dependence and stopping these medications can result in withdrawal symptoms. In addition, 
these medications are most effective when used in long term maintenance, and they do not 
necessarily lead to a patient weaning off of opioids entirely. Treating an opioid use disorder with 
opioids may sound counterintuitive, but both buprenorphine and methadone work to reduce 
cravings, prevent withdrawal symptoms, and reduce illicit opioid use . The effect of methadone 
and buprenorphine on the brain differs from the effect of other opioids such as heroin, fentanyl, 
or oxytocin. While buprenorphine and methadone prevent withdrawal symptoms and cravings, 
they do not produce the type of high or euphoric feelings that other opioids produce. Some of the 
confusion surrounding the use of opioid agonist treatment originates from the imprecise use of 
language used to describe patients with an opioid use disorder.  
Colloquially, addiction is often used interchangeably with opioid use disorder and 
physical dependence to opioids; however, addiction, opioid use disorder, and physical 
dependence are not equivalent. Use of imprecise language can cause confusion when discussing 
the treatment of an opioid use disorder with opioid agonist maintenance. It is important to note 
that even though medically assisted treatment does not entail total detoxification, reversal of 
physical dependence, or abstinence from opioids, it can still enable recovery from an opioid use 
disorder. Tolerance and withdrawal, two signs of physical dependence on opioids, are possible 
criteria for an opioid use disorder according to the Diagnostic and Statistical Manual of Mental 
                                                        
12 Substance Abuse and Mental Health Services Administration, “TIP 63: Medications for Opioid Use Disorder.”  
 
 
 9 
Disorders (5th Edition), but neither of these criteria are met when a patient is taking opioids under 
medical supervision.13 If a patient is taking methadone or buprenorphine solely under medical 
supervision for maintenance therapy, a tolerance to the medication or withdrawal symptoms 
upon stopping the medication would not be criteria that could qualify them for a diagnosis of an 
opioid use disorder. In addition, medically assisted treatment can help to reduce the occurrence 
of other behaviors that can be criteria for the diagnosis of an opioid use disorder, including 
craving for opioids and using a greater quantity of opioids than intended.14  
Opioid use disorder is defined by the Diagnostic and Statistical Manual of Mental 
Disorders (5th Edition), as “a problematic pattern of opioid use leading to clinically significant 
impairment or distress as manifested by at least two of the following, occurring within a 12-
month period: 
1. Opioids are often taken in larger amounts or over longer period than was intended.  
2. There is a persistent desire or unsuccessful efforts to cut down or control opioid use.  
3. A great deal of time is spent in activities necessary to obtain the opioid, use the 
opioid, or recover from its effects.  
4. Craving, or a strong desire to use opioids.  
5. Recurrent opioid use resulting in a failure to fulfill major role obligations at work, 
school, or home.  
6. Continued opioids use despite having persistent or recurrent social or interpersonal 
problems caused or exacerbated by the effects of opioids.  
7. Important social, occupational, or recreational activities are given up or reduced 
because of opioid use.  
                                                        
13 American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders.. 
14 Substance Abuse and Mental Health Services Administration, “TIP 63: Medications for Opioid Use Disorder.”  
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8. Recurrent opioid use in situations in which it is physically hazardous.  
9. Continued opioid use despite knowledge of having a persistent or recurrent physical 
or psychological problem that is likely to have been caused or exacerbated by the 
substance 
10. Tolerance, as defined by either of the following:  
a. A need for markedly increased amounts of opioids to achieve intoxication or 
desired effects 
b. A markedly diminished effect with continued use of the same amount of an 
opioid.  
Note: This criterion is not considered to be met for those individuals taking 
opioids solely under appropriate medical supervision.  
11. Withdrawal, as manifested by either of the following:  
a. The characteristic opioid withdrawal syndrome 
b. Opioids are taken to relieve or avoid withdrawal symptoms.  
Note: This criterion is not considered to be met for those individuals taking 
opioids solely under appropriate medical supervision.” 15 
Most of the criteria which the DSM-5 uses to diagnose OUD are focused the negative 
effects that habitual use of opioids can have on a person’s well-being or quality of life. The 
disorder associated with opioids occurs when a person’s use of opioids causes significant distress 
in their life. With medically assisted treatment, patients continue to use opioids, but they can gain 
more control over how their use of opioids effects their life. Medically assisted treatment with an 
opioid agonist does not necessarily resolve a physical dependence to opioids, but it can 
                                                        
15 American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders. 
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drastically improve the patient’s quality of life and reduce the distress that can be cause by an 
opioid use disorder.  
 
Overview of Buprenorphine Maintenance Treatment:  
 
Buprenorphine is an opioid agonist treatment that has been approved by the FDA for use 
in medically assisted maintenance treatment. Buprenorphine is a partial agonist of the mu-opioid 
receptor and differs in its effects from methadone. Like methadone, buprenorphine is an opiate 
and can reduce the physical symptoms of withdrawal along with cravings. Unlike methadone, 
buprenorphine is a partial agonist. Buprenorphine readily binds to the mu-opioid receptor and 
activates it, but increasing the dose of buprenorphine only increases the effects up to a certain 
point. Once a ceiling dose has been reached, increasing the buprenorphine does not increase its 
effects on the brain.16  
Buprenorphine is used for multiple medical purposes including pain management, 
medically assisted withdrawal, and maintenance treatment. Buprenorphine is often administered 
in a form mixed with naloxone in a 4:1 ratio under the brand name Suboxone. The addition of 
naloxone to the formulation of the medication helps to discourage injection of the medication.17 
Naloxone is a mu-opioid receptor antagonist that has a higher affinity for the receptor than 
buprenorphine. When used as prescribed, the naloxone in Suboxone does not enter the blood 
stream of the patient in a great enough quantity to cause an effect. If a patient were to administer 
Suboxone intravenously, the naloxone would readily enter the blood stream, bind to the mu-
opioid receptors, and can cause withdrawal symptoms.18 Because these withdrawal symptoms 
                                                        
16 Substance Abuse and Mental Health Services Administration, “TIP 63: Medications for Opioid Use Disorder.”. 
17 Substance Abuse and Mental Health Services Administration. 
18 Substance Abuse and Mental Health Services Administration. 
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are often distressing and undesirable, the addition of naloxone to the formulation in Suboxone 
helps to discourage patients from administering the medication intravenously.   
In clinical trials, treatment with buprenorphine maintenance has been shown to have 
superior outcomes when compared to non-pharmaceutical treatment. The Cochrane review 
conducted by Richard Mattick in 2014 analyzed studies comparing buprenorphine to placebo and 
methadone treatment. The outcomes measured in these studies included retention of patients and 
reduction of opioid use. The review included 31 randomized clinical trials that totaled 5430 trial 
participants. They found strong evidence that buprenorphine is more effective than placebo in 
retaining patients and reducing illicit opioid use. The study also found that for patients retained 
in treatment, buprenorphine was equal in its ability to suppress opioid use compared to 
methadone.19 There are pros and cons to using a metanalysis like the Cochrane review to assess 
the efficacy of buprenorphine. The large patient population included in the 31 clinical trials helps 
to support a conclusion that the outcomes in this study would be generalizable to the public at 
large. However, because of the variety in patient factors and types of outcome data that were 
collected across the 31 clinical trial, it can be difficult to statistically analyze the outcomes as an 
aggregate group.   
Buprenorphine is more effective when it is used in long term maintenance therapy than 
when it is used at tapered doses. In a study conducted by Weiss et al. in 2011, 635 patient were 
assigned to a two phase clinical trial aimed at assessing the efficacy of different lengths of 
buprenorphine-naloxone maintenance treatment followed by weaning from treatment. The study 
found that patients who were put on buprenorphine-naloxone treatment for 12 weeks had a 
success rate of 49.2%. 8 weeks after these patients were weaned from treatment, their success 
                                                        
19 Mattick et al., “Buprenorphine Maintenance versus Placebo or Methadone Maintenance for Opioid Dependence.” 
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rate had decreased to 8.6%. These treatment outcomes occurred independently of level of 
counseling or presence of chronic pain as a comorbidity.20 This study shows that buprenorphine 
is far more effective as a maintenance therapy. Buprenorphine is not as effective if used for the 
short term goal of weaning from all opioid agonist treatment.  
In addition to clinical studies, treatment with buprenorphine has also been shown to be 
effective within a natural medical setting in the larger public. In Baltimore, Maryland, an 
increase in the availability of medically assisted treatment starting in 2000 was associated with a 
decrease in the number of heroin overdoses.21 This data is not a controlled study and does not 
account for possible confounding variables. However, when this data is compared to the trend of 
increasing opioid overdose deaths for the entire US during the same time period, the data does 
present compelling evidence that buprenorphine access had a positive impact in reducing 
overdose deaths in Baltimore, Maryland.  
There is also data from other countries that have shown medically assisted treatment to be 
an effective way to reduce overdose deaths. One country that has been successful in reducing the 
number of opioid overdose deaths is France. In France, the number of overdose deaths declined 
by 79% from 1995-1999.22 There are many factors contributing to this decline, but one 
significant change in the country during that time was a 95% increase in the number of patients 
with an opioid use disorder receiving medically assisted treatment.23 In France, most of the 
patient’s receiving buprenorphine are receiving it in a primary care setting. Several aspects of the 
French healthcare setting have made it successful in utilizing buprenorphine as a medically 
                                                        
20 Weiss et al., “Adjunctive Counseling During Brief and Extended Buprenorphine-Naloxone Treatment for 
Prescription Opioid Dependence.” 
21 Schwartz et al., “Opioid Agonist Treatments and Heroin Overdose Deaths in Baltimore, Maryland, 1995–2009.” 
22 Fatseas and Auriacombe, “Why Buprenorphine Is so Successful in Treating Opiate Addiction in France.” 
23 Fatseas and Auriacombe. 
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assisted treatment. All medical doctors in France can prescribe buprenorphine to their patients, 
and the majority of patient receiving buprenorphine treatment are prescribed by a general 
practitioner, not a practitioner in a specialized setting. The organization of the treatment of 
OUDs in a primary care setting also helps to explain the success of increasing treatment access. 
The French system serves as an example of the success that implementation of buprenorphine 
can have in mitigating the opioid epidemic. While this displays the possible benefits of 
increasing buprenorphine access in the United States, there are several pertinent differences 
between the healthcare system in the US and in France. One of the attributes of the French 
healthcare system that facilitates the widespread prescription of buprenorphine is full universal 
coverage for the treatment of opiate dependence. In addition, French primary care physicians are 
also supported by a preexisting network of psychosocial services that can provided for the patient 
free of charge.24  
While buprenorphine does present a viable and life changing treatment option for many 
patients, it is important to note that there are possible risks and consequences of increasing the 
access to buprenorphine. Unfortunately, in the United States there is a history of pharmaceutical 
companies developing and advertising wonder drugs without substantial data to fully understand 
the implications of widespread or chronic use. Buprenorphine has the potential for diversion, 
dependence and misuse. One of the most striking cautionary examples of widespread 
buprenorphine access is the buprenorphine epidemic that occurred in Finland.  
 Finland experiences a marked increase in opioid use disorders with buprenorphine as the 
preferred drug since the introduction of medically assisted treatment in the country in the 1990s. 
A study conducted by Uosakainen et al. looked at the trend in patients seeking treatment for 
                                                        
24 Fatseas and Auriacombe, “Why Buprenorphine Is so Successful in Treating Opiate Addiction in France.” 
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buprenorphine misuse in Finland from 1997-2008. The study was conducted in part because of 
an alarming rise in the number of patients seeking treatment for misuse of high dose 
buprenorphine, which is the dosing that is typically used in opioid substitution treatment. The 
study found that around half of patients seeking treatment for opioid use disorder listed 
buprenorphine as their primary drug. The study also found that from the year 1997-2008, use of 
concurrent drugs increased amongst patients seeking treatment for buprenorphine misuse. 25 The 
authors of the study posited a few possible explanations of this increase in buprenorphine misuse 
in Finland. One compelling explanation was that the access to heroin had been drastically 
decreased while the access to buprenorphine had increased in the country. Another explanation 
was that the production of buprenorphine is likely to be higher quality and more safe that heroin 
because it is typically manufactured by a pharmaceutical company before being diverted to 
unintended uses.26 It is important to note that the source of the buprenorphine that was misused 
by the patients was beyond the scope of this study. Another explanation for the misuse of 
buprenorphine is that patients might be treating their own withdrawal symptoms, essentially 
treating their OUD with buprenorphine outside of the formal healthcare system. As access to 
buprenorphine is expanded in the United States, it is important to learn from countries like 
France and Finland that have already implemented the widespread use of buprenorphine for 
treating OUD. 
 
Introduction to Methadone and Comparisons to Buprenorphine: 
 
                                                        
25 Uosukainen et al., “Twelve-Year Trend in Treatment Seeking for Buprenorphine Abuse in Finland.” 
26 Uosukainen et al. 
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Of the medications used for medically assisted treatment, methadone has the largest 
volume of empirical evidence supporting its efficacy in comparison to non-pharmacological 
treatments. Methadone is a synthetic opiate that acts as a full agonist of the mu-opioid receptor.27 
Because of methadone is an agonist, it can reduce the symptoms of opioid withdrawal and reduce 
a patient’s cravings.28 As a full agonist, increasing the dose of methadone will increase the 
effects of the medication without a ceiling effects. Methadone is used for a variety of medicinal 
purposes including pain management, medically assisted withdrawal, and methadone 
maintenance treatment (MMT). 
In clinical trials, methadone has been shown to be an effective treatment for reducing the 
recurrence of heroin use and cravings for illicit opioids. A study conducted by Mattick et al. for 
the Cochrane Database of Systematic Reviews in 2009 analyzed 11 randomized clinical trials 
containing a total of 1969 participant. These studies focused on the efficacy of methadone 
maintenance treatment compared to abstinence based treatment. This review found that MMT 
was more effective than non-pharmacological treatment for OUD in retaining patient compliance 
and reducing heroin use. The reduction in heroin use was measured both by self-reporting 
measures and urine samples. This study found that methadone and buprenorphine performed 
comparably in reducing heroin use.29  
Like buprenorphine, methadone is more effective as a maintenance therapy than it is as a 
tool for eventual detoxification. A study conducted by Karen Sees et al. and published in the 
Journal of American Medical Association analyzed the efficacy of methadone maintenance 
therapy compared to psychosocially enriched 180-day methadone-assisted detoxification. The 
                                                        
27 Substance Abuse and Mental Health Services Administration, “TIP 63: Medications for Opioid Use Disorder.” 
28 Substance Abuse and Mental Health Services Administration. 
29 Mattick et al., “Methadone Maintenance Therapy versus No Opioid Replacement Therapy for Opioid 
Dependence.” 
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study found that methadone maintenance was relatively more effective than methadone-assisted 
detoxification in decreasing heroin use in patients.30 This supports a conclusion that the most 
effective use of methadone is to reduce craving and prevent withdrawal symptoms while taking 
medication. It is less effective as a tool to reach total detoxification from opioids.  
While methadone might be one of the most empirically supported MATs, it is also the 
most highly regulated medically assisted treatment. Methadone is a schedule II drug and can 
only be administered in an opioid treatment program. Under the Title 21 US Controlled 
Substances Act, a schedule II drug is a drug with currently accepted medical use in the US that 
has a high potential for abuse and may lead to severe psychological or physical dependence. 31 32 
33  Restricting the use of methadone to OTPs can be a barrier for treatment access. One possible 
justification for this heightened surveillance of methadone treatment is the risk of diversion or 
harm to the patient if the medication is not used as prescribed.  
The initial use of methadone can be dangerous if not intensely supervised because of the 
medication’s lengthy and variable half-life lasting around 22 hours.34 The longer half-life of 
methadone can pose some increase in danger for initial use because the concentration of 
methadone in the blood stream over time is less predictable, making it easier to accidently reach 
toxic levels. This unpredictable half-life is one of the reasons that OTPs have strict training for 
methadone maintenance initiation and regulations for maximum dosing at the beginning of 
                                                        
30 Sees et al., “Methadone Maintenance vs 180-Day Psychosocially Enriched Detoxification for Treatment of Opioid 
Dependence.” 
31 The term abuse is used in this instance to refer to the use of opioids in a manner that has not been prescribed by 
a medical provider. Labeling these actions as abuse is common practice in government agencies and legislature, 
but this term can have detrimental effects on the treatment and perception of people with an OUD32 . Because of 
the potential harm that the use of this label can have, the term abuse will only be used when referring to 
government regulations or legislature in the context of this paper.  
32 Kelly, Dow, and Westerhoff, “Does Our Choice of Substance-Related Terms Influence Perceptions of Treatment 
Need?”  
33 Title 21 US Controlled Substances Act. 
34 Toombs and Kral, “Methadone Treatment for Pain States.” 
 
 
 18 
methadone maintenance treatment. It is imperative that steps are taken to ensure that methadone 
maintenance treatment is used to its full potential for opioid use disorders without allowing 
methadone to negatively contribute to the opioid epidemic through diversions and unintended 
use.  
There are many examples of possible risks associated with reducing the regulation of 
methadone. From 2002-2014, methadone related overdose deaths were strongly correlated with 
the rate of prescription of methadone for pain management and rates of diversion of 
methadone.35 The regulation of methadone used for pain management varies from the regulation 
of methadone for MMT in that methadone can be prescribed for chronic pain in an outpatient 
setting by any doctor with proper Drug Enforcement Agency registration. In addition, methadone 
for pain management can be prescribed for multiple take home doses a day, which contrasts the 
restriction that methadone in MMT can only be administered once per day at an OTP.36 Because 
methadone used in an outpatient setting is not under the same strict regulation as methadone used 
in MMT, it is at higher risk of diversion or unintended use. In England and Wales, a study 
conducted by Dr. Marteau and published in the BMJ in 2015 analyzed the comparative risk of 
using methadone or buprenorphine for opioid agonist maintenance treatment for opioid use 
disorders in England. The study found that prescription methadone had a six times higher rate of 
associated overdose death when compared to the risk of overdose when using buprenorphine.37 It 
also found that although the only 36% of the overdose deaths linked to methadone occurred in 
patients who had received the methadone through an MAT program. This suggests that a large 
                                                        
35 Jones et al., “Trends in Methadone Distribution for Pain Treatment, Methadone Diversion, and Overdose Deaths - 
United States, 2002-2014.” 
36 Toombs and Kral, “Methadone Treatment for Pain States.” 
37 Marteau, McDonald, and Patel, “The Relative Risk of Fatal Poisoning by Methadone or Buprenorphine within the 
Wider Population of England and Wales.” 
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portion of the methadone overdoses which occurred in this study resulted from diversion of 
methadone from MAT programs.38 The regulation for methadone maintenance therapy in 
England and Wales differs from the regulations in the United States. Administration of the 
methadone doses used for MMT in England are observed by a pharmacist and are not restricted 
to specialize facilities.39 This system of regulation varies significantly from the US system of 
regulation and displays the risks that are possible if regulations of methadone are reduced. 
Because of the increased risk associated with prescribing methadone, buprenorphine 
tends to be a first line option for patients with an opioid use disorder. There are some instances in 
which methadone maintenance treatment might be preferable to buprenorphine treatment. As a 
partial agonist with a ceiling effect, buprenorphine can be a safer option for many patients. 
However, the ceiling effect of buprenorphine can be problematic if a patient has developed a 
tolerance to opioids that is higher than the ceiling for buprenorphine. In this instance, methadone 
would be a preferred treatment to buprenorphine. In addition, it is important to offer flexibility in 
treatment for patients. The patient population with opioid use disorders is diverse and complex. 
There is no one size fits all for opioid use disorder treatment. While buprenorphine might be a 
better option for one patient because of the convenience of receive it in an outpatient setting, the 
structure required with methadone maintenance treatment at an OTP may help some patients 
with compliance. Ultimately, the expansion of buprenorphine access is likely to be safer and 
equally effective to methadone, although the option for either buprenorphine and methadone 
maintenance treatment should be available to patients who require it.   
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Need for Psychological and Social Services in Addition to OBOT: 
 
There are mixed opinions regarding the necessity of behavioral treatment for patients on 
OBOT. Randomized control studies comparing treatment retention and urine negative samples 
between groups receiving only OBOT and groups receiving OBOT with some form of 
behavioral treatment have had mixed results. It is important to note that negative drug testing is 
not the only possible way to measure the success of a treatment. Behavioral therapy may be a 
benefit for some patients’ quality of life that cannot be measured in a urine test.  
 While buprenorphine is an effective treatment for people with opioid use disorder, 
medication alone is not enough to address the diverse set of needs for people with an opioid use 
disorder. In order for medically assisted treatment to be most effective, there needs to be 
psychological and social resources available to patients. In 2017, 45.6% of adults with a 
substance use disorder also had a cooccurring mental illness. In contrast, of the population 
without a substance use disorder, 16.7% had a cooccurring mental illness.40 The prevalence of 
mental illness is a far greater for patients with a substance use disorder than it is for the 
population of adults without a substance use disorder. Of the adults with both a mental illness 
and substance use disorder, only 8.3% received treatment for both metal health and substance 
use.41 It may be essential to address a patient’s preexisting mental illness before a substance use 
disorder can be addressed.  
 
Need for Access to Buprenorphine and Other Flexible Treatments:  
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 The data presented previously supports the necessity and efficacy of providing access to 
buprenorphine treatment. Evidence supports that maintenance treatment with buprenorphine can 
be a safe, effective, and life changing treatment for patients with opioid use disorder. There is 
compelling evidence from both France and Maryland that increased access to buprenorphine is 
correlated with lower overdose death rates. In addition, there have been a multitude of studies to 
show that buprenorphine is safer than methadone while still being as effective in treating opioid 
use disorders. MAT with buprenorphine is an evidence based and necessary treatment that has 
the capacity to help patient with an opioid use disorder.   
 With over 2 million people in the United States meeting criteria for an opioid use 
disorder, it would be unwise to subscribe a one size fits all solution to this problem. There is just 
as much variation in the population of patients with an opioid use disorder as there is variation in 
the general public. Some patients may need the structured and controlled environment that a 
methadone clinic provides while others find the clinics impersonal and inconvenient. Many 
patients have comorbidities such as other substance use disorders, mental health disorders, or 
chronic pain. Some patients may wish to achieve abstinence while other patients decide to stay in 
MAT for the duration of their life. Buprenorphine should be accessible to all patients who want 
and need it, but it is not the only form of successful treatment. Other common forms of treatment 
include MAT with methadone, MAT with naltrexone, abstinence, social support groups, and 
counseling. A well rounded model for treatment must include access to a variety of treatments or 
have the ability to refer patients to that type of treatment. 
As buprenorphine access is expanded, it is important that concurrent psychosocial 
therapy also be available to the patients. One study found that 93% of providers who were 
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prescribing buprenorphine to their patients felt that patients would benefit from counseling.42 
While the need for psychosocial care is notable, the access to this care is difficult to ensure. Only 
36% of the providers from the study mentioned previously felt that their patients had adequate 
access to counseling. This means that the majority of patients who are being treated in 
community care clinics likely do not have access to the psychosocial care that they might feel 
they need. It is also important to not focus on the medication alone because the environment that 
a person receives medication can have a profound impact on the patient outcome. For this 
reason, many of the programs aimed at expanding access to buprenorphine focus on improving 
the available medical environments in which buprenorphine can be prescribed. One important 
point of analysis is the flexibility of these programs to offer other key forms of treatment to their 
patients. When left alone, many of these primary care providers may be unable to ensure that 
their patients have access to all of the resources they need for recovery. Models of systematic 
support and referral are one way to address some of the common barriers to treatment access and 
to ensure that patients have access to different types of treatment as necessary.  
 
 
PDMPs, Rescheduling Opioids, and the Effect on Patients with Opioid Use 
Disorder  
 
 One of the popular approaches to combating the opioid epidemic is to reduce the number 
of prescriptions for opioids. This is a logical step in trying to reduce the number of new opioid 
use disorders developed. Monitoring and reregulating opioids can reduce the number of 
prescriptions given out each year, and it also is one potential way for medical providers to 
identify patients that might benefit from intervention and treatment for opioid use disorder. 
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These strategies have been successful in reducing the number of prescriptions opioids in 
circulation in the United States. In fact, since 2012, the number of rate of prescriptions for 
opioids has been declining each year. From 2012 to 2017, the number of per capita prescriptions 
for opioid decreased by almost 30%.43 Even though all of the effects of reducing the number of 
prescriptions mentioned previously are beneficial for avoiding new opioid use disorders, there is 
some concern that PDMPs and rescheduling opioids may have negative impacts for patients who 
already have opioid use disorder. Even with the reduction in opioid prescriptions, there continues 
to be a rise in the number of overdose deaths in the US. From 2016 to 2017, there was a 12.0% 
increase in the number of per capita overdose deaths involving an opioid.44 It is concerning that 
as the number of prescriptions for opioids has reduced, the number of overdose deaths has 
continued to rise. This is only correlational data, and there could be several factors contributing 
to this continued rise in overdose deaths. However, there is concern that if a patient has an opioid 
use disorder from prescription opioids and can no longer gain access to an opioid prescription 
through legal means, they may seek out illegal sources of opioids such a heroin or fentanyl. 
There illegal sources of opioids are more dangerous and carry a higher risk of overdosing. This is 
not to say that a doctor should continue to prescribe opioids to patients who have an opioid use 
disorder, but they should have the ability to provide help or refer these patients to sources of help 
rather than just cutting off a patient and leaving them without support. As opioids are subject to 
more stringent regulation and prescription drug monitoring programs become more common, it 
is important that there is adequate treatment resources to address subsequent patients who may 
need help. The emphasis on reducing the amount of prescription opioids in circulation is a 
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beneficial step for future reduction of the opioid use disorders. Unfortunately, the reduction in 
the number of prescriptions since 2012 has not yet correlated with a reduction in the number of 
patients with opioid use disorder. This does not necessarily mean that these efforts have been 
ineffective, but it does show that simply reducing the supply of opioids is not enough to address 
the prevalence of opioid use disorders in the United States.   
Chapter 2: Barriers to Access for Buprenorphine and the Need for 
Systemic Support 
 
Even though buprenorphine has been shown to be a relatively safe and effective 
treatment for patients with an opioid use disorder, there are still large gaps in the availability and 
utilization of this treatment. The initial dissemination of buprenorphine has not occurred as 
quickly or as equally as initially intended. The gaps in treatment are important to acknowledge 
and address. These treatment gaps have many sources including prescriber scarcity, geographic 
isolation, economic disparities, and demographic inequalities. These factors can be addressed 
through the use of institutional systems and programs within healthcare. This chapter of the 
thesis aims to assess the current gaps in access to buprenorphine and the need for systems of 
support to close these gaps in access. FDA approval for buprenorphine as a treatment of opioid 
use disorders might provide legal availability to treatment, but this does not address any of the de 
facto barriers to access. Many of these barriers may not be addressed through the natural 
diffusion of MAT into medical practice and there is an need for programs that directly address 
these barriers.  
 
Supply Side Restrictions on Buprenorphine Access 
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 This section aims to assess the barriers to access that are created by a scarcity of 
providers in the US who are DATA waivered and have the capacity to take on new OBOT 
patients. Increasing supply side access requires increasing the number of providers who are 
DATA waivered, willing to prescribed buprenorphine, and have the capacity and desire to treat 
the maximum number of buprenorphine patients allowed. There are many factors that affect the 
supply of providers who are able and willing to provide this type of care for patients including 
FDA regulations, lack of provider interest and incentive, and the uncertainty regarding which 
specialty should be responsible for providing this care.   
One of the major factors effecting the access to buprenorphine is its regulation under US 
law. Buprenorphine is a schedule III drug and can only be administered by a health care provider 
if they obtain a waiver. The waiver program is regulated with the Drug Abuse Treatment Act of 
2000 (DATA 2000). Physicians who have met the requirement to obtain a waiver under this act 
are often called DATA waivered physicians. Under the current iteration of DATA 2000, an MD, 
NP, or PA can manage a maximum of 30 patients with buprenorphine for MAT during the first 
year as a buprenorphine prescriber. After a year of treating 30 patients, an MD, NP, or PA can 
increase their maximum patients to 100 people. After one year of treating 100 patients, only a 
physician can increase the number of their patients to 275.45 A physician can qualify to obtain a 
waiver to prescribed buprenorphine after attending an eight hour continuing education course. A 
physician assistant or nurse practitioner can qualify for a buprenorphine waiver following 24 
hours of training.46 Nurse practitioners and physician assistance may be required to be under the 
supervision of a physician who has obtained the qualifications for a buprenorphine waiver, 
depending on the state regulation. Both the 8 hour and 24 hour training options are available 
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online and free of cost through multiple site including the Providers Clinical Support System. 
After obtaining a waver to prescribe buprenorphine, a medical provider can prescribe take home 
dosing of buprenorphine for MAT. Because increasing the number of physicians who have 
obtained a waiver is more cost efficient than creating new opioid treatment facilities, increasing 
access to buprenorphine should be relatively easier than increasing access to methadone in the 
United States.  
As the number of DATA waivered physicians increases, the number of patients that can 
receive buprenorphine treatment should also theoretically increases. An investigation published 
in JAMA found that, amongst Medicaid enrollees, a 10% increase in the number of DATA 
waivered medical providers was associated with a 10% increase in buprenorphine prescribing 
rate.47 While this may seem like an obvious correlation to establish, it also supports several 
fundamental ideas underpinning the efforts to increase access. The first of these ideas is that 
increasing the number of DATA waivered physicians has the potential to increase the number of 
patients receiving treatment. The second fundamental idea is that there is unmet demand for 
buprenorphine treatment. While it is well established that there is unmet need for treatment, there 
are many patients who might need treatment but either want a form of treatment that is not 
buprenorphine or do not wish to pursue treatment. This study helps to establish that there are 
patients who would receive buprenorphine treatment if more providers were available to 
prescribe it.  
One of the questions surrounding the expansion of access to buprenorphine treatment is 
the division of responsibility for this form of treatment amongst the fields of medicine. While 
addiction medicine might be the most obvious choice to carry the majority of the responsibility, 
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the number of addiction specialists in the United States is too small to support the need for 
treatment. Although there are around 2 million patients in the United States with an opioid use 
disorder, there are only 5,500 physicians trained in addiction psychiatry or addiction medicine.48 
It is also important to note that opioid use disorder is not the only disorder that is considered part 
of the addiction specialty. There is a large number of other substance use disorders that can also 
put a strain on the capacity of the physicians in addiction specialties to provide care for all the 
patients who need it. While there are efforts to increase the number of physicians trained in 
addiction medicine and psychiatry, the need for treatment must be addressed in the interim. The 
DATA waiver program does not require the medical provider to come from a specialty, and one 
proposed solution to the bottle neck created by the lack of addiction specialist is to move some of 
the management of opioid use disorders into the primary care setting. Primary care physicians 
are tasked with managing many complicated chronic conditions such as diabetes, 
hyperlipidemia, and hypertension, with the support of a referral system for patients requiring 
specialty care. Many people argue that a similar system would work well for outpatient 
buprenorphine maintenance. Less complex patients can receive treatment from a primary care 
physician, while more complex cases are referred to addiction specialist. While buprenorphine 
can carry some risk, there are plenty of other complex medications that are often managed by 
primary care including insulin and anti-hypertensive medication. In the same manner that 
diabetes and hypertension are too prevalent in the population for endocrinologist and cardiologist 
to manage every case, opioid use disorder is also too prevalent to be only treated by psychiatrists 
and addiction specialists. In addition, opioid use disorder is not the only behavioral health 
condition that is commonly treated by primary care. Many primary care providers prescribe 
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antidepressants, mood stabilizers, and antianxiety medications to their patients. One other 
important implication of providing treatment for opioid use disorder in a primary care setting is 
that it may be able to reduce some of the stigma associated with opioid use disorder and with 
seeking treatment for opioid use disorder. It is possible that with the right support, primary care 
physicians could be able to treat many of the patients requiring OBOT.  
Providing treatment for opioid use disorder through primary care physicians has several 
advantages. The number of primary care physicians currently practicing in the United States, 
including family medicine, general practice, and internal medicine, is 332,216.49 In addition, 
primary care physicians are the front line of care and might be the only point of contact with the 
health care system for some patients. Some studies have found that patients with an alcohol or 
substance use disorder are more likely to initiate treatment if it is offered at a primary care 
setting.50 There are several possible explanations for this phenomena. One of the most cited 
reasons for not entering treatment is that patients do not perceive a need for treatment and do not 
want others to know that they are receiving treatment.51 Receiving care at a primary care office is 
less likely to feel like to patient is receiving intensive care. After all, many people need to make 
regular appointments with their primary care provider for a range of chronic health conditions. It 
may be that a patient fears stigma if they are seen at or near an opioid treatment program. 
Another reason for this preference of treatment in a primary care setting is the convenience. 
Patients may feel more comfortable navigating the structure of an outpatient clinic, as this is the 
setting in which many other common conditions are addressed. Even though primary care is a 
potential area of growth for treatment of opioid use disorder, there are challenges associated with 
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expanding the number of primary care physicians offering this treatment and ensuring quality of 
care.  
While the number and location of primary care physicians might make them a viable 
option for increasing access to buprenorphine, there are many obstacles to expanding this form 
of treatment in primary care. In practice, increasing the treatment capacity for buprenorphine 
maintenance has been more complicated than simply providing free DATA waiver classes. Even 
though these classes can be taken for free, the time to take these classes is not compensated. 
Only 3% of primary care physicians were DATA waivered in 2015.52 In addition, younger 
physicians were less likely to have obtained a DATA waiver.53 This indicates that the physicians 
who are coming out of residency programs are not likely to seek out a DATA waiver. This data 
contrasts studies that have found that there is significant interest amongst new residents to 
become DATA waivered. One study found that amongst the internist attending physicians and 
residents surveyed in the study, 66.7% had high interest in obtaining a DATA waiver.54 The 
physicians were more likely to be interested in obtaining a DATA waiver if they were younger or 
had a strong belief that buprenorphine was an effective treatment for opioid use disorder. While 
this study cannot necessarily be generalized to all internists or primary care physicians, it shows 
that the interest in obtaining a DATA waiver is likely to be far greater than the 3% of physicians 
who currently are DATA waivered. This indicates the need for some form of intervention within 
the medical community to connect interested physicians to training. Another obstacle for 
expanding treatment into a primary care setting is the concern that adding more strain to the 
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primary care workload would facilitate worsening provider burnout. Primary care physicians are 
already tasked with understanding and managing a wide variety of complex chronic and acute 
conditions. For many primary care physicians that already feel overwhelmed by the broad 
spectrum of medical conditions that they are expected to competently manage, taking an 
uncompensated class to expand their patient load might not be an enticing option. It is important 
to ensure that primary care physicians feel supported as they take on treatment of opioid use 
disorder in order to prevent increasing physician burn out.  
In addition, simply obtaining a DATA waiver does not necessitate that the medical 
provider will be willing or able to take on patients needing buprenorphine treatment. A study 
conducted by Jones et. al. electronically surveyed 4225 clinicians who had obtained a federal 
DATA waiver in 2017 to determine common barriers or incentives for providers to prescribe 
buprenorphine after obtaining a waiver. The study found that 24.5% of the surveyed providers 
had not prescribed buprenorphine to a patient, even though they were legally able to. In addition, 
only 13.1% of the providers were prescribing close to the limit of patient’s allowed by the 
waiver. 55  This is a major barrier to treatment. If a provider who is able to prescribed 
buprenorphine is not willing to prescribe it, then they do not contribute to increasing access to 
treatment. This article shows that simply increasing the number of DATA waivered physicians is 
not enough to efficiently increase access. It would be unfortunate to spend tremendous effort to 
incentivize physicians to obtain a DATA waiver only to find that they do not use their new 
capacity to actually treat patients. The study found that increased patient interest, increase 
institutional support, and increased reimbursement were three of the incentives that providers 
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considered most promising for increasing the number of patients receiving buprenorphine.56 
Another study found that primary care physicians site a lack of training, poor care coordination, 
and inadequate institutional support as some of the major factors for not prescribing 
buprenorphine.57 Many physicians may feel that the 8 hour course required to obtain a DATA 
waiver is insufficient to gain competence in treating a medical condition as complex and variable 
as opioid use disorder. The complexities caused by cooccurrence of other substance use 
disorders, chronic pain, and other mental health disorders, can discourage primary care 
physicians from initiating treatment. In addition, the connection between patients who need 
treatment and the physicians who can provide treatment appears to be lacking. All of these 
barriers decrease the potential for buprenorphine to reach its full potential in reducing the 
occurrence of opioid use disorder and opioid overdoses in the US.  
 
Geographic Barriers to Access 
 
Another problem facing access to buprenorphine treatment is geographical distribution of 
physicians. Rural areas tend to have less access to specialty care, including treatment for opioid 
use disorder. Providing quality specialty care in rural settings is not an issue isolated to opioid 
use disorder treatment. Rural areas tend to be further from academic hospitals and specialty care 
clinics. In 2017, 56.3% of rural counties in the United States did not have any physicians that 
were DATA waivered. Rural areas also have a lower per capita access to DATA waivered 
physicians. It can be difficult to ensure access to a DATA waivered physician in a rural area for 
several reasons. Because rural providers are tasked with caring for patients that do not have 
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access to specialists, they can have practices that are already strained with complex patient loads. 
In addition, the number of physicians in rural areas are less than urban areas so the likelihood of 
one of these prescribers being DATA waivered is smaller than in urban areas. Providing medical 
care in rural areas can be challenging, and it is important to address these geographic barriers 
when expanding access to buprenorphine maintenance for opioid use disorder.  
One example of a state within the US that faces geographic difficulty in providing quality 
care for opioid use disorder is Texas. In 2017, Texas had an estimated population of 28,797,290 
people dispersed over 268,596 square miles.58 The population of Texas is concentrated in urban 
areas, but around 3,230,468 people in Texas live in non-metropolitan areas. 59 These non-
metropolitan areas can be hours from the nearest metropolitan area when traveling by car. In the 
2015-2016 National Survey on Drug Use and Health conducted by SAMHSA, it was estimated 
that Texas had 1,026,000 people who had misused opioid within a one month period. Of this 
group, 306,000 people lived in small metropolitan or non-metropolitan areas.60 Approximately 
one third of people misusing opioids were located in non-metropolitan areas. While misuse of 
opioids is not equivalent to having an opioid use disorder, recurrent misuse of opioids is one of 
the possible criterium for diagnosing an opioid use disorder and is likely to be correlated with a 
risk for developing an opioid use disorder. In addition to the prevalence of opioid misuse outside 
of large metropolitan areas, the rate of opioid overdoses per 100,000 people is higher in rural 
communities in the US according to the Morbidity and Mortality Weekly Report release by the 
CDC in 2017.61 Both of these studies serve to highlight the evident need to provide access to 
treatment in rural communities.  
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According to data collected by SAMHSA, there are 83 SAMHSA-certified OTP clinics 
which offer methadone for opioid use disorder treatment in Texas.62 These clinics are 
concentrated around areas of higher population. While there are OTPs within a reasonable 
distance in urban areas, many of the non-metropolitan areas are far from the nearest OTP. In 
addition to OTPs, there are 838 DATA waivered medical providers in Texas listed in the 
SAMSHA database.63 The distribution of these providers is similar to the distribution of the OTP 
clinics. The number of OTPs is geographically correlated with the concentration of the 
population.  
Another problem facing care in a rural setting is the scarcity of supporting care such as 
psychosocial care. In the US, 65% of the non-metropolitan counties do not have any 
psychiatrists, 47% do not have psychologists, and 27% do have social workers.64 This means that 
only expanding access to buprenorphine access is not enough to ensure that patients get the most 
effective and flexible care. Most patients would likely benefit from a multidisciplinary approach 
to treatment that incorporates medical professionals, behavioral health specialist, and social 
workers. Access to any or all of these resources is especially difficult to ensure in rural areas. It 
is important the providers in rural settings feel equipped and supported with the necessary 
resources to treat patients with a opioid use disorder.  
 
Demographic Barriers to Access 
 
 There has been a long history in the US of disparity in treatment based on the 
demographic profile of the patient. In addition, this disparity has been especially apparent in the 
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treatment of substance use disorders. Access to buprenorphine has been shown to be unequal 
amongst race and ethnicities. Counties with higher percentages of traditionally underserved 
minorities, such as African American and Hispanic populations, are less likely to have access to 
a DATA waivered medical provider.65 66 Another study found there is an uneven distribution of 
buprenorphine usage between different zip codes within a county, with higher percent wealthy 
white communities being more likely to use buprenorphine for treatment.67 This same study 
found that there was a positive correlation between counties that had higher percent poverty with  
African America or Hispanic populations and the use of methadone treatment. This indicates that 
there is a need and demand for treatment of opioid use disorders within these communities. It is 
likely that many members of the communities that have a higher percent poverty or are 
composed of a higher percent African American of Hispanic population would want access to 
buprenorphine. Some have argued that the association between racial minorities and methadone 
has contributed to the increased regulation of methadone.  
 The rate of increase in the number of buprenorphine prescribers by county is not equal 
across counties with various ethnic demographics.  Although access to buprenorphine treatment 
has increased over time, the rate of increase is faster for areas where less of the population is 
composed of Hispanic or African American residents.68 This is problematic for ensuring access 
to treatment because it indicates that the demographic disparities can continue to persist or even 
worsen over time. It is essential that programs which focus on increasing the number of 
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buprenorphine waivered providers are aware that some demographics are disproportionately 
underserved. Programs should aim to ensure that the increase in buprenorphine providers also 
occurs in areas that traditionally have less access to care.     
 Another important demographic factor that must be mentioned is financial barriers to 
treatment. In the 2017 National Survey of Drug Use and Health conducted by SAMHSA, 30.3% 
of the people who perceived a need for treatment of substance sue disorder but did not receive it 
cited cost of treatment without insurance coverage as their primary barrier. The frequent doctors 
visits, lab work, monitoring, medication, and transportation can all be cost prohibitive for 
patients. Financial barriers to access are mentioned briefly here because it is a significant barrier 
to access; however, a full discussion concerning the causes and solutions to the issue of funding 
in medicine is beyond the scope of this thesis.   
 
Patient Education and Access to Treatment  
 
Not every patient that qualifies as having an opioid use disorder wants to enter treatment. 
Of the patients who needed but did not receive substance use disorder treatment in the National 
Survey on Drug Use and Health, 94.3% cited that they did not perceive a need for treatment.69 It 
is important that patients are educated on treatment in a variety of setting in order to reduce 
stigma surrounding treatment seeking. While many patients would benefit from some sort of 
treatment and have an increase in their quality of life, it may be that the stigma surrounding 
treatment is too great of a barrier for them to overcome. In addition, many patients may not know 
that there are pharmaceutical options for treatment of opioid use disorder that are offered outside 
of rehabilitation facilities. If efforts were made to increase intervention and patient education it 
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would likely increase the number of patients who are interested in receiving treatment for an 
opioid use disorder.  
Chapter 3: Innovations in Expanding Access and Quality of OBOT 
 
The barriers presented in the previous section all highlight issues that have not been 
naturally addressed by the diffusion of buprenorphine into healthcare. There are clearly problems 
facing expanded access to buprenorphine that may not be solved without efforts that specifically 
target these issues. There have been several models for addressing these issues that have been 
proposed. Some of these models are specific to addressing opioid use disorder while other 
programs have borrowed models that have been effective when treating other health conditions.  
Each of the following models aim to address some of the barriers to access by providing 
support for the DATA waivered provider and the patient receiving treatment. In the following 
section, four models for systematic support are discussed: telemedicine, hub and spoke models, 
nurse care managers, and hospital initiation of buprenorphine. These tools are discussed in the 
context of actual programs that have been implemented in the US. While the programs discussed 
in this next section are by no means comprehensive, they give a good overview of the variety of 
strategies currently used in the US to expand access. Many of the programs discussed in the next 
section incorporate multiple strategies; however, each is used as an example for a specific type of 
innovation.  
 
The Use of Telemedicine in OBOT: Project ECHO 
 
 Telemedicine is the use of technology, usually video conference calls, to help disseminate 
information remotely. The term telemedicine is typically used to describe the remote 
communication between medical providers and their patients; however, telemedicine has also 
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been employed in communication between different health care providers to disseminate 
information and facilitate educational programs. Technological advancements that allow for 
video conferences and fast reliable communication between doctors have already begun to 
impact medicine positively. Telemedicine has been implemented in programs addressing some of 
the treatment gaps in OBOT, primarily gaps in the supply of providers prescribing buprenorphine 
and geographical distribution of care. One of the programs which has used telemedicine to 
address treatment gaps is the ECHO program in New Mexico.  
 Project ECHO (Extension for Community Healthcare Outcomes) was first implemented 
in 2003 at the University of New Mexico Health Science Center. The program was designed by 
Dr. Sanjeev Arora in order expand the access to quality care for patient with Hepatitis C virus 
(HCV). Dr. Sanjeev Arora identified a significant need for increasing quality care for HCV in the 
rural areas of New Mexico. He saw technology as one possible method for addressing this need. 
The ECHO program connects office based practices throughout the state to experts in the field of 
study located at teleECHO hubs, which are typically at academic hospitals. The program uses 
video technology to facilitate virtual seminars and helps to disseminate information on best 
practices to a team of community providers, increasing their ability to confidently and effectively 
treat complex conditions.70  
Project ECHO was shown to be effective in safely treating patients with Hepatitis C. The 
New England Journal of Medicine published a study that assessed the outcomes of patients that 
had been treated for Hepatitis C by a primary care doctor who had been in the ECHO program 
and compared these outcomes to patients that were treated at university medical centers.71 The 
study found that patients treated at clinics using the ECHO model had equal rates of sustained 
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viral response and serious adverse events as those treated at the University of New Mexico HCV 
clinic. This study showed that ECHO could be safely used to implement treatment for complex 
conditions in clinics that were not specialized in that area of treatment. One of the explanations 
for the success of the program was that continuity of care and proximity of care are superior to 
initiating care with a new, distant provider. Because of the success of this program in HCV, it 
has been expanded to be used for a multitude of complex chronic conditions, including opioid 
use disorder.  
Project ECHO for opioid use disorder is a system of regularly scheduled video 
conferences. Each week, multiple video conferences are held in which primary care providers 
can present their patient cases to experts located at a teleECHO hub. The teleECHO sessions can 
be conducted by an interdisciplinary team of experts including “addiction specialist, a 
psychiatrist, a licensed clinical social worker with addiction expertise, a psychiatric nurse or 
psychiatric nurse specialist, and a community health worker”.72 The sessions last 2 hours and 
include both a didactic portion and a case-based learning portion. Through presentation and 
discussing real deidentified cases, all of the providers in the session can learn from the input and 
experience of other primary care physicians and experts in the field of addiction medicine.  The 
idea is that the providers are able to gain competency in treating a complex conditions through 
the ongoing training and mentorship. In additions, providers can learn from each other by 
hearing and discussing all of the patient cases. By using real patient cases as the basis for the 
teleECHO session, the doctors are exposed to the complexities that exist within the actual 
population of patients with an opioid use disorder.  
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Through this model of information dissemination and doctor mentorship, the ECHO 
program begins to address some of the significant barriers to safely increasing buprenorphine 
access in outpatient office settings. The ECHO model has had success in increasing access to 
treatment in New Mexico. One study found that since the start of the ECHO program focused on 
substance use disorders, the increase in DATA waivered physicians located in traditionally 
underprivileged areas in New Mexico increased at a rate that exceeds the rest of the United 
States.73 This is a significant impact of this program because it contrasts the trends in growth of 
provider access for the rest of the United states, in which the demographic disparities have 
resulted in slower growth for areas that are composed of traditionally underserved populations. 
There is not yet conclusive data on patient outcomes relating to the ECHO model when used for 
treating substance use disorders, but there have been good outcomes for patients treated by 
ECHO clinics for other conditions, such as HCV. In addition, initial surveys have shown a 
promising response from health care providers involved in an ECHO program. This type of 
program is especially useful in states where the rural population cannot easily access specialty 
care due to distance from metropolitan areas.  
 This model has many beneficial attributes that make it a viable option for safely 
expanding the access to MAT with buprenorphine. The programs targets teams of providers, 
including a lead provider and a nurse or medical assistant. This type of model directly targets the 
problem of rural access. It not only allows for an increase in the number of competent DATA 
waivered medical providers, it also allows providers to feel confident in expanding the number 
of patients that they can see. This helps to address the issue of DATA waivered physicians who 
do not take on the maximum number of patients allowed by their waiver. In addition, models 
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such as the ECHO model allows for quality control to maintain the optimal standard of care 
because doctors across the state are provided with information coming from the same source. 
This also allows for quick dissemination of information as new data emerges and best practices 
change. There is also some flexibility in this model for doctors to have control over how they 
decide to integrate MAT with buprenorphine into their practice.  
 There are some possible concerns with this model of treatment for opioid use disorders. 
The first of these concerns is that the ECHO model does not resolve the time strain that treating 
opioid use disorders can have on primary care physicians. Treatment with buprenorphine can be 
time intensive because of the initiation and the close monitoring required to ensure the best 
patient care. Also, attending the ECHO video conferences takes time and physicians are not 
compensated for their participation. This can mean that participation in project ECHO actually 
creates a greater uncompensated time strain for the participating physicians. While project 
ECHO addresses issues of geographic access and increases the patient capacity for participating 
physicians, it does not ensure that the patients have access to other treatments such as methadone 
maintenance or counseling. Given that this program targets rural areas, it is definitely worth 
noting that access to some forms of treatment is better than access to no forms of treatment. 
However, project ECHO alone cannot solve the issues of ensuring access to a variety of recovery 
options. In conclusion, the strongest attributes of project ECHO are that it addresses barriers 
created by geographic distribution and reduces supply side restrictions caused by prescribers who 
feel ill-equipped to treat patients to the full capacity of their DATA waiver. Project ECHO is an 
effective way to use technology to increase access to treatment for opioid use disorders.  
 
Hub and Spoke Models: Vermont, Maryland, and Rhode Island 
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 Many of the hub and spoke models for treating OUD were developed from the Health 
Homes Models that were introduced under the Affordable Care Act of 2010. States were given 
the option to use federal funding to create Health Homes that could facilitate the coordination of 
care for Medicaid enrolled patients who were at risk of developing multiple chronic conditions, 
such as opioid use disorder. The intention of the program was to provide six key health services 
including comprehensive care management, core coordination, health promotion, comprehensive 
transitional care, individual and family support, and referral to community and social support 
services.74 The programs aim to create a robust network of providers within one system that are 
able to provide comprehensive care. By connecting these providers into one system, care of 
patients can be coordinated and there can be “warm hand offs” when it is necessary to transfer a 
patient. In addition, patients within the system are supposed to have all of the resources in the 
system at their disposal. There are three states that have adopted Medicaid health home models 
specifically for patients with an opioid use disorder: Maryland, Vermont, and Rhode Island. 
While each of these programs is slightly different, they all operate within the health home model.  
The Medicaid health homes in Vermont are part of a system called the hub and spoke 
model. The Hub and Spoke model was first popularized in Vermont and is also called the Care 
Alliance for Opioid Addiction. Unlike the ECHO model previously discussed, this model was 
originally designed as a response to the opioid epidemic in Vermont. This system divides the 
clinical settings that are involved in buprenorphine treatment into two categories, hubs and 
spokes. Hubs are typically specialty outpatient treatment programs (OTPs) that offer methadone 
and buprenorphine, and spokes are outpatient practices that offer buprenorphine for office-based 
opioid treatment (OBOT). Hubs are intended to be fully staffed with medical providers and 
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counselors that specialize in substance use disorder treatment. Spokes are located in primary care 
settings and typically are staffed with a team of providers including a DATA waivered physician, 
nurse, and a master’s level counselor. The hub and spoke program emphasizes that each of the 
spoke cites includes integrated psychosocial care.75 In addition to the DATA waivered 
physicians at the spokes, for every 100 Medicaid patients receiving OBOT there is also one nurse 
and a master’s level behavioral health provider in a supportive role. Patients can transfer between 
the hub and the spoke depending on their current level of complexity and need for specialty care. 
Communication between the hub and the spoke concerning particular cases is conducted by a 
registered nurse or a case manager. Patients typically receive their initial screening at hubs. At 
the time of this initial screening, the hub staff determines the most appropriate level of care for 
the patient. Patients can continue care at the OTP hub, or they can be transferred to a spoke 
provider. The spoke provider continues to have access to the specialist at the hub if they require 
guidance.  
In 2017, the Vermont Department of Health funded a preliminary evaluation of the hub 
and spoke model, which was conducted by Dr. Rawson at the University of Vermont Center for 
Behavior and Health.76 The review collected both quantitative and qualitative data regarding the 
efficacy of the hub and spoke program. The patients interviewed for this study had an average 
history of 14 years of opioid use and were either treated with methadone at one of the hub sites 
or buprenorphine at a spoke site. The evaluation found that participants within the hub and spoke 
system in Vermont had improved in their substance use habits, including an average 96% 
decrease in opioid, decreased use of other substances like alcohol and tobacco, and reduction of 
emergency department visits. Patients in the hub and spoke model also reported having positive 
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improvements in lifestyle, including a decrease in illegal activity, increased life satisfaction, and 
decreased instances of conflict with their family. These outcomes highlight the effect of 
medically assisted treatment in producing positive patient outcomes. Within this 2017 evaluation 
of the hub and spoke model, 40 of the participant were located at a hub site and 40 participants 
were located at a spoke site. This facilitated the collection of data that was useful in comparing 
the advantages and disadvantages of both types of sites. A common theme in the data collected 
was that patients at hub sights had higher satisfaction with the mental health services offered.  
 There are many benefits to the hub and spoke model that can be used in other states. One 
of the important tools of the hub and spoke model is the care coordinator and the ease of transfer 
from primary care settings to specialty clinics. One of the main barriers to successfully treating 
opioid use disorder with medically assisted treatment is patient compliance. If a patient begins to 
destabilize in an outpatient setting and needs to be transferred to more specialized care, then it is 
important that there is systematic support to ensure that the patient is successfully transferred 
from a spoke to a hub or vice versa. In addition, the integration of care for opioid use disorders 
into one system in the state of Vermont can help to ensure quality and consistency in the care 
provided. The hub and spoke model in Vermont has attempting to increase dissemination of 
information and homogeny of care by implementing didactic video conference sessions. By 
using a state wide, hub and spoke system, there is an infrastructure for referring patients as well 
as connecting physicians to mentors and ongoing support.  
 One of the major advantages of this model is that all of the different resources necessary 
for effective and comprehensive care for a patient with opioid use disorder can be housed under 
the same roof. This makes it more convenient for a patient to access all of these services. It also 
facilitates communication between the different branches of treatment and can allow for a 
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multidisciplinary and holistic approach to patient care. This allows for more flexible treatment 
for the patient.  
 There have been several challenges associated with implementing Medicaid health homes 
for opioid use disorder. One of the identified barriers for these programs was a lack of providers 
willing to be a part of the care system. This type of model typically relies on preexisting OTPs 
within the state to act as the hubs. Community care clinics that can act as spokes can be 
increased through outreach, but it is more resource intensive to create new OTPs. Another barrier 
facing the initiation of these programs is provider burnout during times of transition. It is 
important that providers involved in the programs feel invested in the programs and do not feel 
forced into compliance and change when unnecessary.  
 
Nurse Care Managers and Collaborative Care Team Models: The 
Massachusetts Model  
 Nurse care managers present one promising form of systematic support for the treatment 
of OBOT in a primary care setting. Nurse care managers are typically implemented within a 
collaborative care model of treatment. This model can be used to treat several chronic conditions 
and has been shown to be effective when used in the treatment of patients with an opioid use 
disorder. Collaborative care focuses on addressing the difficultly surrounding the extensive 
monitoring that is typically carried out during OBOT by using the nurse care manager to carry 
out much of the follow up. A study by Alford et. Al., conducted in 2011, showed that patients 
who were treated within a collaborative care model had good success with OBOT. Slightly more 
than half of the patients were retained in treatment at 12 months and of the patients who were 
retained 91.1% were abstinent from illicit opioids. Another study found that the collaborate care 
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model used in a primary care setting increased the number of patients receiving treatment and the 
number of patients who were abstinent at 6 months.77 One example of a program that has used 
collaborative care to expand access to OBOT treatment is the Massachusetts program.   
 The model for systematic support of OBOT in Massachusetts is called the State 
Technical Assistance Treatment Expansion Office-Based Opioid Treatment Program (STATE 
OBOT-B) and relies on a collaborative care model for office base buprenorphine treatment. This 
model for was first implemented in community health centers in 2007. The program was 
developed to address five key barriers to treatment in the state. These five barriers were 
physician competing activities, lack of support staff, inadequate addiction expertise, payment 
issues, and administrative obstacles.78 An integral part of the effort to address these issues is the 
use of nurse care managers. Nurse care managers are nurses who are specifically hired and 
trained to care for the patients receiving OBOT. The nurse care managers work closely with a 
DATA waivered medical providers and other care team members to help alleviate some of the 
barriers to treatment. In addition to the nurse care managers, the program also puts an emphasis 
on education and training for all of the staff involved in OBOT through TTAs (Training and 
Technical Assistance) One of the goals of the program was to ensure treatment of traditionally 
underserved patients. The nurse care manager performs the initial screening and medical 
induction. In addition, they serve as a liaison between the patient and the DATA waivered 
provider and stay in close contact with the patient with follow up visits to ensure that the patient 
is successful initiated on treatment and receiving behavioral health counseling. The 
Massachusetts model puts an emphasis on the entire team of health care providers involved in 
the treatment. On-site training was provided to the entire clinical staff with the primary purpose 
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of reducing stigma and improving care quality for OUD patients. Community care clinics that 
met state standards were given a grant to fund one full time nurse care manager with the 
expectation that the nurse care manager would be responsible for around approximately 100 
patients receiving buprenorphine. Of note, after the start of the program, 5 of the original 19 
clinics that had opted to take part in this program returned their contracts because they were 
unable to meet the standards of the state.79 There are several advantages of using a nurse care 
manager for OBOT. One of the major barriers preventing physicians from taking on 
buprenorphine patients is the perceived time constraint and low reimbursement. Using a nurse 
care manager helps to alleviate this perceived time constraint. In addition, the nurse care 
manager ensure consistent follow up and monitoring.  
 There is some preliminary data collected from 2007-2013 which indicates that the 
Massachusetts model can be an effective model for systematic support of OBOT.  Since the 
implementation of this model, the number of DATA waivered providers and the number of 
patient’s receiving treatment with OBOT both increased. The patients treated within the 
Massachusetts collaborate care model showed good retention, with 67% of patients retained in 
treatment for more than 12 months. This indicates that frequent visits with the nurse care 
manager can be an effective alternative to being closely followed by an MD or midlevel 
provider.  
 
Initiating Buprenorphine Maintenance at Hospitals 
 
Patients have two basic forms of accessing information about treatment, either they seek 
this information out or someone else brings this information to their attention. Each point of 
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contact with the medical system is an opportunity for a health care professional to share 
information about opioid use disorder and treatment with the patient. One of the currently 
underutilized medical settings for disseminating information and initiating treatment is the 
hospital setting, both emergency department and inpatient. Studies have shown that intervention 
and initiation of treatment in hospital settings can be one way to increase a patient’s likelihood to 
engage in treatment. Many hospitals have begun to adopt programs that focus in intervention, 
initiation of treatment, and referral to outpatient management with good success. This next 
section discusses the data supporting this type of program and the variations within hospital 
initiated OBOT.  
 This type of program takes a different approach to expanding access to treatment than the 
programs previously discussed. Unlike telemedicine, hub and spoke models, and collaborative 
care models, this program focuses only on the initiation of treatment and the ability to refer for 
further treatment. This type of program was included for analysis because it uses a resource 
which is already available, the hospital system, and creates another opportunity for intervention. 
An ER visit or a hospitalization might be the first time a patient comes to the realization that they 
would like to receive help treating their opioid use disorder. In addition, the hospital setting can 
provide the patient a brief break from their surroundings that might contribute negatively to their 
opioid use disorder. It is important to capitalize on the time that a patient spends in the hospital 
so that a patient is able to make their decision regarding treatment without the pressure of outside 
influences in their lives.  
 Initiation of OBOT in the hospital is intended to utilize a patient’s time in the hospital to 
identify potential opioid use disorder, begin treatment, and connect the patient to appropriate 
care after they are discharged. Hospitals may be the only point of care for patients who might not 
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otherwise have regular contact with a medical professional. Many patient who have opioid use 
disorder require hospitalization for a number of reason. One common cause for hospitalization is 
opioid overdose. The number of emergency department visits for opioid overdoses increased 
30% from 2016 to 2017. In addition, patients with an opioid use disorder may need 
hospitalization for a number of other health complications relating to chronic opioid use. Some 
patients with an opioid use disorder may be at the hospital for an unrelated health condition or 
acute injury. No matter the reason for a patients visit to the hospital, if they have an opioid use 
disorder, then their time in the hospital can be used to inform them of their treatment options and 
hopefully improve their future health outcome. Hospital initiation of buprenorphine typically 
occurs in three stages: screening, intervention, and initiation. 
 Screening for patients that potentially have an opioid use disorder is typically done in a 
questionnaire format. There are several advantages of using questionnaires. It is beneficial for 
screening tools to be brief and easy to use so that they can be readily implemented in the setting 
of an emergency department. There are a variety of concerns when a patient enters an ER and 
opioid use might not be the most pressing or evident problem for that patient. It is important that 
the screening be accurate, but not take up more time than necessary. Questionnaires are more 
susceptible to inaccuracy than other forms of screening such as drug screening because patients 
can lie or withhold information on a survey. However, there are several questionnaires that have 
been used successfully to identify patients who could benefit from intervention and further 
treatment.80 There is also some variability in the types of patients that receive screening. It would 
by inefficient to screen every patient in the hospital for opioid use disorders due to time 
constraints and other pressing concerns. Patients who screen positive for an opioid use disorder 
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or concerning opioid use patterns are then typically given a brief intervention. If the patient is 
interested in starting treatment after this intervention, then the hospital can initiate buprenorphine 
while the patient is still in the hospital.   
 A study conducted by Liebschutz et al. analyzed the outcomes for patients that were 
initiated on buprenorphine treatment during hospitalization when compared to the patient that 
underwent a 5 day detoxification.81 The patients that were assigned to the buprenorphine 
maintenance were also linked to the hospital’s primary care clinic buprenorphine OAT. The 
study found that patients who were induced on buprenorphine treatment in the hospital had 
improved outcomes in many measures including entry into buprenorphine OAT after discharge, 
reduced illicit opioid use, and retention in buprenorphine maintenance treatment.82 This study 
provides valuable data supporting the programs that operate within a hospital setting to initiate 
treatment and link patients to continued care.  
 Initiation onto buprenorphine treatment during hospitalization has been shown to be more 
effective in increasing enrollment in outpatient buprenorphine treatment than intervention and 
referral alone. D’Onofrio et. Al. conducted a study in 2015 in which 329 patient were assigned to 
three interventions: referral only, intervention and referral, or buprenorphine/naloxone initiation 
and referral. The study found that the patients who were initiated onto buprenorphine during 
hospitalization were more likely to be engaged in treatment one month after the study 
intervention. This indicates that while a robust referral system is essential to connect patients to 
care, more patient will actually follow up and seek treatment if treatment is initiated while they 
are still in the hospital. Initiation onto buprenorphine takes time and effort. Providing the 
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initiation of buprenorphine in the hospital makes the initial treatment more convenient for the 
patient.83 
 While there is good data to support the implementation of this program, many hospitals 
have been slow to adopt a model of emergency department initiation of buprenorphine 
maintenance treatment. A survey of physicians working in emergency departments found that 
barriers to implementing this type of program include lack of patient interest, insufficient referral 
network, and insufficient provider comfort for prescribing buprenorphine and determining the 
necessary level of care.84 Many of the patient who are identified in an emergency department as 
qualifying for buprenorphine maintenance treatment are not likely to be seeking treatment at the 
time of their hospitalization. This may explain why there is a lack of patient interest. The referral 
network is key for the implementation of this program. If a patient is initiated onto 
buprenorphine but then has nowhere to follow up for continued maintenance, then their treatment 
is more similar to a buprenorphine detox and release than to the start of OBOT. The insufficient 
provider comfort may be the most readily addressable barrier to implementing models like ER 
and inpatient initiation of buprenorphine. Offering education, training, and mentorship to doctors 
who may want to prescribe buprenorphine but feel uncomfortable with their level of competency 
would be an effective step towards decreasing this barrier.  
 Similar to many of the models assessed in this thesis, the emergency department initiation 
of OBOT relies heavily on coordinated transfer of patients from one point of care to another. 
This system cannot be successful if there is not a network of medical providers who are DATA 
waivered, willing to prescribed buprenorphine, and can take on new patients. While the 
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emergency department initiation of buprenorphine is a good model for areas with a readily 
available outpatient buprenorphine treatment, it does little on its own to address the shortage of 
physicians who are willing and able to manage a patients on buprenorphine.   
  
Comparing Innovations 
 
 The models previously discussed each use innovative tools and organization in order to 
address the issues surrounding buprenorphine access in the United States. While each of these 
models address a variety of the barriers to access, some of the programs are better suited for 
addressing certain types of access barriers than others. In assessing and comparing all of these 
programs, the benefits and setbacks of each model can be seen more apparently, which can be 
informative as new models for treatment are designed and implemented.  
One of the barriers that these programs begin to address is the inadequate number of 
providers who are DATA waivered and willing to take on more patients. The two programs that 
addressed this issue most directly were project ECHO and the collaborative care model. Both of 
these programs targeted current DATA waivered providers and attempted to provide the 
resources for the provider to treat more patients. The collaborative care model and project ECHO 
are distinct in several capacities. Project ECHO expands access by addressing a lack of 
experience and education for treatment of opioid use disorders while collaborative care addresses 
the perceived time strain that taking on new patients with OUD can have on a provider’s 
schedule. Project ECHO attempts to address a need for more highly trained specialists, while the 
collaborative care model actually offloads a large portion of the monitoring and follow up onto 
the nurse care managers, who presumably have less training than the physician. These two 
models are similar in that they delegate care and disseminate information from a smaller group 
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of medical professionals to a larger group of professionals who have less training. In project 
ECHO, information and treatment is disseminated from a team of specialists to a primary care 
team so that the primary care team can make an independent decision as to the best course of 
treatment for their patient. The specialist team in project ECHO is not responsible for the patient 
care decisions. This differs from the collaborative care model because the decisions for the 
patient are a collaborate effort between the nurse care manager and the provider. In addition, in 
the collaborative care model both of the parties are responsible for the patient’s care. While at 
first these two systems seem to be at odds, both systems increase access to buprenorphine 
treatment in a safe and effective way. This indicates that both of the models for expanding access 
are filling a need that is not currently met. The treatment of opioid addiction is similar to other 
chronic conditions in that a highly trained medical provider is sometimes necessary, but it is not 
essential that every interaction with the patient be carried out by a highly specialized MD in 
order to provide quality care. At the core, project ECHO and the collaborative care model 
actually are very similar. Both ensure that patients receive high quality care by disseminating 
information and responsibility to the providers with the appropriate level training for that level of 
care. Ultimately, it appears that project ECHO is the most effective program for increasing the 
capacity of DATA waivered physicians in rural area. Collaborate care is better suited for urban 
settings.   
Another consideration for evaluating these programs is the degree of strain that they can 
cause on the medical providers. With any change or increase in a providers practice, there is 
always the potential for provider burnout. As new programs are implemented, it is important to 
take into account ways to minimize the strain on the medical providers who participate. The 
programs which are more likely to cause provider strain are those that are organized and 
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regulated by statewide programs, such as Hub and Spoke and Collaborative Care. While 
statewide programs allow for closer monitoring and can facilitate consistency in the type of care 
offered, they can often be less flexible in their  design and implementation. Project ECHO and 
emergency department initiation of buprenorphine are both less likely to cause physician burnout 
when compared to the other two programs. Both project ECHO and emergency department 
initiation of buprenorphine focus on giving current providers new tools for treating patients. Both 
of these programs give individual clinics and hospitals more autonomy in how they want to 
implement the use of these tools within their practice. These more flexible programs can be 
beneficial because it is unlikely that there is one way of implementing a program that will work 
well across an entire state. Physicians are able to choose how many patients to take on and in 
what case load they feel they can handle. This contrasts the Medicaid health home models and 
coordinated care models because physicians who participate become a part of a system. 
Providers might feel greater pressure and expectation to treat more patients because they are a 
part of a greater system of health care providers. In addition, clinics that cannot meet the 
standard set by the State are unable to participate in these programs at all. These less flexible 
programs can be beneficial because they may spur clinics to increase their quality of care and the 
resources that they offer. Project ECHO and hospital initiation of buprenorphine are both models 
of care that can be regulated by each individual clinic or hospital, allowing for more autonomy 
and flexibility. This contrasts the Medicaid health home and coordinated care models which can 
provide structured and consistent quality of care across the state but do not allow for as much 
flexibility.  
  In addition, there are significant differences in the delegation of the responsibility of care 
between the different programs. In contrast with many of the other models patient’s treated 
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within the ECHO framework are not ever directly under the care of an expert in the field of 
addiction medicine. In fact, the case information presented in the ECHO telecommunication 
clinics is deidentified. While this allows for treatment of patients who might not have geographic 
access to an OTP or specialty clinic it can also reduce the ability to maintain continuity of care 
for patients who destabilize and require more structured care in an OTP. Under the hub and 
spoke model, the transfer of patients from a spoke back to a hub is intended to be a well-
coordinated continuation of care. If the patient destabilizes in office based treatment and requires 
a more structured or intensive program, their care can be transferred to an OTP that still has 
contact with the spoke cite. If a primary care provider in the Hub and Spoke model requests 
assistance from the Hub, it is likely that they will be able to discuss the patient case with a 
provider who actually knows and has had contact with that patient.  
 The programs previously mentioned have several qualities in common that are essential 
to their successful. All of the programs rely on providers who share a common belief in the 
efficacy and necessity of buprenorphine for opioid use disorder. Stigma against patients with 
opioid use disorder and the treatment of opioid use disorder continues to be a common issue in 
the United States. Without providers who are willing to manage patients with an opioid use 
disorder, none of these programs would function. It is also important that the entire health care 
team involved in the treatment are working together to increase the efficacy of buprenorphine 
maintenance. Another important determinant of success for these programs is the cooperation 
between health care providers and professionals in other disciplines in order to create continuity 
of quality care.  
 
A Case from Travis County  
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 One example of an area that could benefit by expanding access to buprenorphine is 
Austin, Texas. In 2016, the rate of deaths from opioid overdoses was 7.5 per 100,000 in Travis 
county. 85 Although this number is lower than the national average of 13.1 per 100,000 in 2016, 
it is likely that the number of opioid overdose deaths in Texas are underreported. According to 
the SAMHSA buprenorphine practitioner locator, there are currently 92 DATA waivered 
medical providers in Travis County.86 In addition, CommUnity Care has partnered with Integral 
care to provide buprenorphine as part of the hospital district for Travis county. CommUnity Care 
operates with a hub and spoke model of care, with the hub sight located at the Dove Springs 
clinic in Austin. Because Travis county is a large urban area with an existing hub and spoke 
system, it would be beneficial to expand the capacity of the hub and spoke system by creating 
more hub cites that could house multidisciplinary teams focused on treating opioid use disorder. 
It would be important to have a more coordinated system of referral and treatment established 
within Travis county before attempting to implement hospital initiation of buprenorphine. One of 
the ways to expand the capacity of the hub and spoke model may be to integrate nurse care 
managers within the treatment team. While all of these programs provide some benefit in 
expanding access to buprenorphine, Travis county would most benefit from expanding the hub 
and spoke system and integrating nurse care mangers into the treatment teams.  
Conclusion: 
 
 Thousands of people die of opioid overdoses every year in the United States, but 
expanding access to buprenorphine is one of the many hopeful innovations being explored to 
combat this opioid epidemic. Buprenorphine has been shown to be effective in decreasing the 
                                                        
85 Huang et al., “Drug Overdose and Opioid Use in Travis County.” 
86 SAMHSA, “SAMHSA Behavioral Health Treatment Facility Listing 2018.” 
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rates of overdose deaths, and it has helped many patients recover from opioid use disorder and 
improve their quality of life. There is an evident need for expansion of access to medically 
assisted treatment with buprenorphine. It is imperative that access to buprenorphine be safely 
increased in order to address the current need for opioid use disorder treatment. While 
buprenorphine has been FDA approved for 16 years, there continues to be limited access to this 
treatment. Some of the factors limiting access include a lack of DATA waivered prescribers who 
can take on new patients, geographic barriers, limited access to flexible treatment, and 
demographic disparities in access. In order to ensure that buprenorphine maintenance is 
accessible to all people who need it for opioid use disorder, programs designed specifically for 
the purpose of improving OUD treatment and buprenorphine access must be implemented. The 
programs highlighted within this thesis can be useful tools when addressing the current barriers 
to access.  
In conclusion, all four models are effective in addressing some of the barriers for 
treatment. When assessing and comparing these models, it is important to take into account the 
most pressing of the issues in the region being analyzed. If the issue of treatment is the 
geographic distances, then models that rely on the presence of a nearby OTP will be less 
effective in treating rural patients when compared to models such as project ECHO. This is 
contrasted by states that are densely populated and need better care coordination within the state. 
These densely populated states would likely benefit most from coordinated care models and 
Medicaid health home models. The emergency department initiation of buprenorphine is most 
likely to be effective in states which have extensive networks of treatment that a patient can be 
referred to upon leaving the hospital.  
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 Ultimately, each of these models has had some success in improving access to 
buprenorphine while ensuring quality care. It would be wonderful to have all of these programs 
working in conjunction within a state; however, with limited funding and the urgency of finding 
solutions to reduce opioid use disorder prevalence, each state will need to make decisions as to 
which parts of these programs are most necessary and pressing at that time. Just as there is no 
one size fits all treatment for opioid use disorder, there is also no one size fits all program for 
expanding access to buprenorphine in the United States. The variety in demographics, funding, 
and geography within a region will ultimately determine which of these programs will be most 
beneficial in expanding access to MAT with buprenorphine  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 58 
Works Cited  
 
Abraham, Amanda J., Grace Bagwell Adams, Ashley C. Bradford, and William D. Bradford.  
  “County-Level Access to Opioid Use Disorder Medications in Medicare Part D (2010- 
  2015).” Health Services Research https://doi.org/10.1111/1475- 
  6773.13113. 
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th  
  ed. Arlington, VA: American Psychiatric Publishing, 2013. 
Andrilla, C. Holly A., Tessa E. Moore, Davis G. Patterson, and Eric H. Larson. “Geographic  
  Distribution of Providers With a DEA Waiver to Prescribe Buprenorphine for the  
  Treatment of Opioid Use Disorder: A 5-Year Update.” The Journal of Rural Health 35,  
  no. 1 (2019): 108–12. https://doi.org/10.1111/jrh.12307. 
Arora, Sanjeev, Karla Thornton, Glen Murata, Paulina Deming, Summers Kalishman, Denise  
  Dion, Brooke Parish, et al. “Outcomes of Treatment for Hepatitis C Virus Infection by  
  Primary Care Providers.” New England Journal of Medicine 364, no. 23 (June 9, 2011):  
  2199–2207. https://doi.org/10.1056/NEJMoa1009370. 
Barry, Colleen L., Andrew J. Epstein, David A. Fiellin, Liana Fraenkel, and Susan H. Busch.  
  “Estimating Demand for Primary Care-Based Treatment for Substance and Alcohol Use  
  Disorders.” Addiction 111, no. 8 (2016): 1376–84. https://doi.org/10.1111/add.13364. 
“CDC Reports Rising Rates of Drug Overdose Deaths in Rural Areas.” CDC Press Releases,  
  October 19, 2017. https://www.cdc.gov/media/releases/2017/p1019-rural-overdose- 
  deaths.html. 
Center for Behavioral Health Statistics and Quality. “2017 National Survey on Drug Use and  
  Health: Detailed Tables.” Substance Abuse and Mental Health Services Administration,  
  Rockville, MD., 2018. 
D’Onofrio, Gail, Patrick G. O’Connor, Michael V. Pantalon, Marek C. Chawarski, Susan H.  
  Busch, Patricia H. Owens, Steven L. Bernstein, and David A. Fiellin. “Emergency  
  Department–Initiated Buprenorphine/Naloxone Treatment for Opioid Dependence: A  
  Randomized Clinical Trial.” JAMA 313, no. 16 (April 28, 2015): 1636–44.  
  https://doi.org/10.1001/jama.2015.3474. 
Duber, Herbert C., Isabel A. Barata, Eric Cioè-Peña, Stephen Y. Liang, Eric Ketcham, Wendy  
  Macias-Konstantopoulos, Shawn A. Ryan, Mark Stavros, and Lauren K. Whiteside.  
  “Identification, Management, and Transition of Care for Patients With Opioid Use  
  Disorder in the Emergency Department.” Annals of Emergency Medicine 72, no. 4  
  (October 1, 2018): 420–31. https://doi.org/10.1016/j.annemergmed.2018.04.007. 
Fatseas, M., and Marc Auriacombe. “Why Buprenorphine Is so Successful in Treating Opiate  
  Addiction in France.” Current Psychiatry Reports 9, no. 5 (October 1, 2007): 358–64.  
  https://doi.org/10.1007/s11920-007-0046-2. 
US Census Bureau. “State Area Measurements and Internal Point Coordinates.”  
  Accessed December 13, 2018. https://www.census.gov/geo/reference/state-area.html. 
Haffajee, Rebecca L., Amy S. B. Bohnert, and Pooja A. Lagisetty. “Policy Pathways to Address  
  Provider Workforce Barriers to Buprenorphine Treatment.” American Journal of  
  Preventive Medicine, The Behavioral Health Workforce: Planning, Practice, and  
  Preparation, 54, no. 6, Supplement 3 (June 1, 2018): S230–42.  
  https://doi.org/10.1016/j.amepre.2017.12.022. 
 
 
 59 
Hansen, Helena B., Carole E. Siegel, Brady G. Case, David N. Bertollo, Danae DiRocco, and  
  Marc Galanter. “Variation in Use of Buprenorphine and Methadone Treatment by Racial,  
  Ethnic and Income Characteristics of Residential Social Areas in New York City.” The  
  Journal of Behavioral Health Services & Research 40, no. 3 (July 2013).  
  https://doi.org/10.1007/s11414-013-9341-3. 
Hansen, Helena, Carole Siegel, Joseph Wanderling, and Danae DiRocco. “Buprenorphine and  
  Methadone Treatment for Opioid Dependence by Income, Ethnicity and Race of  
  Neighborhoods in New York City.” Drug and Alcohol Dependence 164 (01 2016): 14– 
  21. https://doi.org/10.1016/j.drugalcdep.2016.03.028. 
Huang, Phillip, Sarah Seidel, Haruna Miyakado Steger, Jeff Taylor, and David Zane. “Drug  
  Overdose and Opioid Use in Travis County.” Travic County Medical Society Journal 64,  
  no. 2 (April 2018): 24–26. 
James, Jocelyn R., Leah M. Gordon, Jared W. Klein, Joseph O. Merrill, and Judith I. Tsui.  
  “Interest in Prescribing Buprenorphine among Resident and Attending Physicians at an  
  Urban Teaching Clinic.” Substance Abuse 0, no. 0 (March 26, 2018): 1–3.  
  https://doi.org/10.1080/08897077.2018.1449176. 
Jones, Christopher M., Grant T. Baldwin, Teresa Manocchio, Jessica O. White, and Karin A.  
  Mack. “Trends in Methadone Distribution for Pain Treatment, Methadone Diversion, and  
  Overdose Deaths - United States, 2002-2014.” Atlanta, United States, Atlanta: U.S.  
  Center for Disease Control, July 8, 2016.  
  https://search.proquest.com/docview/1806004590/abstract/55C7188F919D4823PQ/1. 
Jones, Christopher M., and Elinore F. McCance-Katz. “Characteristics and Prescribing Practices  
  of Clinicians Recently Waivered to Prescribe Buprenorphine for the Treatment of Opioid  
  Use Disorder.” Addiction, October 15, 2018. https://doi.org/10.1111/add.14436. 
Kelly, John F., Sarah J. Dow, and Cara Westerhoff. “Does Our Choice of Substance-Related  
  Terms Influence Perceptions of Treatment Need? An Empirical Investigation with Two  
  Commonly Used Terms.” Journal of Drug Issues 40, no. 4 (October 1, 2010): 805–18.  
  https://doi.org/10.1177/002204261004000403. 
Komaromy, Miriam, Dan Duhigg, Adam Metcalf, Cristina Carlson, Summers Kalishman, Leslie  
  Hayes, Tom Burke, Karla Thornton, and Sanjeev Arora. “Project ECHO (Extension for  
  Community Healthcare Outcomes): A New Model for Educating Primary Care Providers  
  about Treatment of Substance Use Disorders.” Substance Abuse 37, no. 1 (2016): 20–24.   
  https://doi.org/10.1080/08897077.2015.1129388. 
Korthuis, P. Todd, Dennis McCarty, Melissa Weimer, Christina Bougatsos, Ian Blazina,  
  Bernadette Zakher, Sara Grusing, Beth Devine, and Roger Chou. “Primary Care-Based  
  Models for the Treatment of Opioid Use Disorder: A Scoping Review.” Annals of  
  Internal Medicine 166, no. 4 (February 21, 2017): 268–78. https://doi.org/10.7326/M16- 
  2149. 
LaBelle, Colleen T., Steve Choongheon Han, Alexis Bergeron, and Jeffrey H. Samet. “Office- 
  Based Opioid Treatment with Buprenorphine (OBOT-B): Statewide Implementation of  
  the Massachusetts Collaborative Care Model in Community Health Centers.” Journal of  
  Substance Abuse Treatment, Special Issue on Studies on the Implementation of Integrated  
  Models of Alcohol, Tobacco, and/or Drug Use Interventions into Medical Care, 60  
  (January 1, 2016): 6–13. https://doi.org/10.1016/j.jsat.2015.06.010. 
Larson, Eric, Davis Patterson, Lisa Garberson, and C. Holly Andrilla. “Supply and Distribution  
  of the Behavioral Health Workforce in Rural America.” WWAMI Rural Health Research  
 
 
 60 
  Center, University of Washington, September 2016. 
Liebschutz, Jane M., Denise Crooks, Debra Herman, Bradley Anderson, Judith Tsui, Lidia Z.  
  Meshesha, Shernaz Dossabhoy, and Michael Stein. “Buprenorphine Treatment for  
  Hospitalized, Opioid-Dependent Patients.” JAMA Internal Medicine 174, no. 8 (August  
  2014): 1369–76. https://doi.org/10.1001/jamainternmed.2014.2556. 
Lin, Lewei (Allison), Michelle R. Lofwall, Sharon L. Walsh, and Hannah K. Knudsen.  
  “Perceived Need and Availability of Psychosocial Interventions across Buprenorphine  
  Prescriber Specialties.” Addictive Behaviors 93 (June 1, 2019): 72–77.  
  https://doi.org/10.1016/j.addbeh.2019.01.023. 
Marteau, Dave, Rebecca McDonald, and Kamlesh Patel. “The Relative Risk of Fatal Poisoning  
  by Methadone or Buprenorphine within the Wider Population of England and Wales.”  
  BMJ Open 5, no. 5 (May 1, 2015): e007629. https://doi.org/10.1136/bmjopen-2015- 
  007629. 
Mattick, Richard P., Courtney Breen, Jo Kimber, and Marina Davoli. “Buprenorphine  
  Maintenance versus Placebo or Methadone Maintenance for Opioid Dependence.”  
  Cochrane Database of Systematic Reviews, no. 2 (2014).  
  https://doi.org/10.1002/14651858.CD002207.pub4. 
Mattick, Richard P., Courtney Breen, Jo Kimber, and Marina Davoli. “Methadone Maintenance  
  Therapy versus No Opioid Replacement Therapy for Opioid Dependence.” Cochrane  
  Database of Systematic Reviews, no. 3 (2009).  
  https://doi.org/10.1002/14651858.CD002209.pub2. 
Moses, Kathy, and Klebonis. “Designing Medicaid Health Homes for Individuals with Opioid  
  Dependency: Considerations for States.” Center for Health Care Strategies, January 2,  
  2015. https://www.chcs.org/resource/designing-medicaid-health-homes-individuals- 
  opioid-dependency-considerations-states/. 
National Center on Health Statistics. “National Overdose Deaths from Select Prescription and  
  Illicit Drugs,” August 2018. 
“Our Story | Project ECHO.” Accessed May 7, 2019. https://echo.unm.edu/about-echo/ourstory. 
“Population Data (Projections) for Texas Counties, 2017.” Accessed December 13, 2018.  
  https://www.dshs.texas.gov/chs/popdat/ST2017.shtm. 
Portenoy, Russell K., and Kathleen M. Foley. “Chronic Use of Opioid Analgesics in Non- 
  Malignant Pain: Report of 38 Cases.” Pain 25, no. 2 (May 1, 1986): 171–86.  
  https://doi.org/10.1016/0304-3959(86)90091-6. 
“Professionally Active Primary Care Physicians by Field.” The Henry J. Kaiser Family  
  Foundation (blog), October 17, 2018. https://www.kff.org/other/state-indicator/primary- 
  care-physicians-by-field/. 
Rawson, Richard. “Vermont Hub-and-Spoke Model of Care for Opioid Use Disorders: An  
  Evaluation.” Vermont Center on Behavior and Health Department of Psychiatry, n.d. 
Rosenblatt, Roger A., C. Holly A. Andrilla, Mary Catlin, and Eric H. Larson. “Geographic and  
  Specialty Distribution of US Physicians Trained to Treat Opioid Use Disorder.” Annals  
  of Family Medicine 13, no. 1 (January 2015): 23–26. https://doi.org/10.1370/afm.1735. 
SAMHSA. “Key Substance Use and Mental Health Indicators in the United States: Results from  
  the 2017 National Survey on Drug Use and Health (HHS Publication No. SMA 18-5068,  
  NSDUH Series H-53).” Rockville, MD: Center for Behavioral Health Statistics and  
  Quality, Substance Abuse and Mental Health Services Administration, n.d. 
SAMHSA. “National Survey on Drug Use and Health 2016.” 2016. 
 
 
 61 
SAMHSA. “SAMHSA Behavioral Health Treatment Facility Listing 2018.” SAMHSA, 2018. 
Schwartz, Robert P., Jan Gryczynski, Kevin E. O’Grady, Joshua M. Sharfstein, Gregory Warren,  
  Yngvild Olsen, Shannon G. Mitchell, and Jerome H. Jaffe. “Opioid Agonist Treatments  
  and Heroin Overdose Deaths in Baltimore, Maryland, 1995–2009.” American Journal of  
  Public Health 103, no. 5 (March 14, 2013): 917–22.  
  https://doi.org/10.2105/AJPH.2012.301049. 
Sees, Karen L., Kevin L. Delucchi, Carmen Masson, Amy Rosen, H. Westley Clark, Helen  
  Robillard, Peter Banys, and Sharon M. Hall. “Methadone Maintenance vs 180-Day  
  Psychosocially Enriched Detoxification for Treatment of Opioid Dependence: A  
  Randomized Controlled Trial.” JAMA 283, no. 10 (March 8, 2000): 1303–10.  
  https://doi.org/10.1001/jama.283.10.1303. 
Sokol, Robert, and Kevin Kunz. “Training Future Physicians to Address Opioid Crisis.” AAMC  
  News. Accessed March 2, 2019. https://news.aamc.org/patient-care/article/training- 
  future-physicians-address-opioid-crisis/. 
Substance Abuse and Mental Health Services Administration. “TIP 63: Medications for Opioid  
  Use Disorder.” U.S. Department of Health and Human Services, February 2018. 
The Henry J. Kaiser Family Foundation. “Opioid Overdose Death Rates and All Drug Overdose  
  Death Rates per 100,000 Population (Age-Adjusted).” Accessed May 7, 2019.  
Title 21 US Controlled Substances Act, § 812 (n.d.). 
Toombs, James D., and Lee A. Kral. “Methadone Treatment for Pain States.” American Family  
  Physician 71, no. 7 (April 1, 2005): 1353–58. 
Uosukainen, Hanna, Jussi Kauhanen, Sari Voutilainen, Jaana Föhr, Mika Paasolainen, Jari  
  Tiihonen, Kirsti Laitinen, Ifeoma N. Onyeka, and J. Simon Bell. “Twelve-Year Trend in  
  Treatment Seeking for Buprenorphine Abuse in Finland.” Drug and Alcohol Dependence  
  127, no. 1 (January 1, 2013): 207–14. https://doi.org/10.1016/j.drugalcdep.2012.07.002. 
“U.S. Opioid Prescribing Rate Maps | Drug Overdose | CDC Injury Center,” October 29, 2018.  
  https://www.cdc.gov/drugoverdose/maps/rxrate-maps.html. 
Watkins, Katherine E., Allison J. Ober, Karen Lamp, Mimi Lind, Claude Setodji, Karen Chan  
  Osilla, Sarah B. Hunter, et al. “Collaborative Care for Opioid and Alcohol Use Disorders  
  in Primary Care: The SUMMIT Randomized Clinical Trial.” JAMA Internal Medicine  
  177, no. 10 (October 1, 2017): 1480–88.  
  https://doi.org/10.1001/jamainternmed.2017.3947. 
Weiss, Roger D., Jennifer Sharpe Potter, David A. Fiellin, Marilyn Byrne, Hilary S. Connery,  
  William Dickinson, John Gardin, et al. “Adjunctive Counseling During Brief and  
  Extended Buprenorphine-Naloxone Treatment for Prescription Opioid Dependence: A 2- 
  Phase Randomized Controlled Trial.” Archives of General Psychiatry 68, no. 12  
  (December 5, 2011): 1238–46. https://doi.org/10.1001/archgenpsychiatry.2011.121. 
Wen, Hefei, Jason M. Hockenberry, and Harold A. Pollack. “Association of Buprenorphine- 
  Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid  
  Use in Medicaid Enrollees.” JAMA Network Open 1, no. 5 (September 7, 2018):  
  e182943–e182943. https://doi.org/10.1001/jamanetworkopen.2018.2943. 
Wilkerson, Richard Gentry, Hong K. Kim, Thomas Andrew Windsor, and Darren P. Mareiniss.  
  “The Opioid Epidemic in the United States.” Emergency Medicine Clinics of North  
  America 34, no. 2 (May 2016): e1–23. https://doi.org/10.1016/j.emc.2015.11.002. 
 
 
 
 62 
 Elizabeth A. Stratton was born in Austin, Texas on November 8, 1996. She enrolled in 
Biology and the Plan II Honors Program at the University of Texas at Austin in 2015. In college, 
she was a YoungLife leader at Austin High School and worked as a medical scribe. She 
graduated in 2019 and plans to attend PA school in May of 2020. 
